Sotera Health (NASDAQ:SHC) Issues FY24 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.67-0.75 for the period, compared to the consensus earnings per share estimate of $0.72. The company issued revenue guidance of $1.09-1.11 billion, compared to the consensus revenue estimate of $1.11 billion. Sotera Health also updated its FY 2024 guidance to 0.670-0.750 EPS.

Analysts Set New Price Targets

SHC has been the topic of several analyst reports. Citigroup increased their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. Barclays upped their target price on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a research report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Sotera Health presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Sotera Health Stock Up 3.0 %

Shares of Sotera Health stock traded up $0.47 on Wednesday, reaching $15.89. The company’s stock had a trading volume of 929,339 shares, compared to its average volume of 1,304,662. The firm’s fifty day simple moving average is $15.94 and its two-hundred day simple moving average is $13.67. The company has a market capitalization of $4.50 billion, a price-to-earnings ratio of 112.93 and a beta of 2.08. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The company has a quick ratio of 2.59, a current ratio of 2.93 and a debt-to-equity ratio of 5.46.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. Sotera Health’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.18 earnings per share. Equities analysts anticipate that Sotera Health will post 0.64 earnings per share for the current year.

Insider Buying and Selling at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 55.12% of the stock is owned by insiders.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.